Jose Nativi-Nicolau
Overview
Explore the profile of Jose Nativi-Nicolau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rebello S, Hsu K, Nativi-Nicolau J, Karam C, Grogan M, Lousada I, et al.
Amyloid
. 2025 Feb;
:1-10.
PMID: 39950841
Introduction: Transthyretin (ATTR) amyloidosis is an ultimately fatal disease. While approved therapies slow disease progression, the cost of care can be significant for patients. The objective of this survey was...
2.
Judge D, Gillmore J, Alexander K, Ambardekar A, Cappelli F, Fontana M, et al.
Circulation
. 2024 Nov;
151(9):601-611.
PMID: 39556242
Background: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary...
3.
Nativi-Nicolau J, Yilmaz A, Dasgupta N, Macey R, Cochrane J, Peatman J, et al.
J Comp Eff Res
. 2024 Jun;
13(7):e230158.
PMID: 38869839
The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis...
4.
Gillmore J, Judge D, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al.
N Engl J Med
. 2024 Jan;
390(2):132-142.
PMID: 38197816
Background: Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer that acts to inhibit dissociation of tetrameric...
5.
Lyle M, English S, Goswami R, Leoni Moreno J, Nativi-Nicolau J, Yip D, et al.
J Heart Lung Transplant
. 2023 Jun;
42(10):1481-1483.
PMID: 37268053
Donation after circulatory death (DCD) is becoming increasingly utilized in heart transplantation and has the potential to further expand the donor pool. As transplant cardiologists gain more familiarity with DCD...
6.
Sperry B, Hanna M, Maurer M, Nativi-Nicolau J, Floden L, Stewart M, et al.
JAMA Cardiol
. 2023 Feb;
8(3):275-280.
PMID: 36723935
Importance: Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations and minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis. However, the clinical significance of health status...
7.
Kittleson M, Ruberg F, Ambardekar A, Brannagan T, Cheng R, Clarke J, et al.
J Am Coll Cardiol
. 2023 Jan;
81(11):1076-1126.
PMID: 36697326
No abstract available.
8.
Carnicelli A, Keane R, Brown K, Loriaux D, Kendsersky P, Alviar C, et al.
Resuscitation
. 2022 Dec;
183:109664.
PMID: 36521683
Background: Cardiac arrest (CA) is a common reason for admission to the cardiac intensive care unit (CICU), though the relative burden of morbidity, mortality, and resource use between admissions with...
9.
Brannagan 3rd T, Berk J, Gillmore J, Maurer M, Waddington-Cruz M, Fontana M, et al.
J Peripher Nerv Syst
. 2022 Nov;
27(4):228-237.
PMID: 36345805
Transthyretin-mediated amyloidosis (ATTR) is a rare, under-recognized, progressively debilitating, fatal disease caused by the aggregation and extracellular deposition of amyloid transthyretin (TTR) fibrils in multiple organs and tissues throughout the...
10.
Malkani S, Nativi-Nicolau J
Rev Esp Cardiol (Engl Ed)
. 2022 Oct;
76(4):218-219.
PMID: 36302468
No abstract available.